261 related articles for article (PubMed ID: 29073233)
1. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
2. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
3. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
4. Retinal Vascular Abnormalities and Microglia Activation in Mice with Deficiency in Cytochrome P450 46A1-Mediated Cholesterol Removal.
Saadane A; Mast N; Trichonas G; Chakraborty D; Hammer S; Busik JV; Grant MB; Pikuleva IA
Am J Pathol; 2019 Feb; 189(2):405-425. PubMed ID: 30448403
[TBL] [Abstract][Full Text] [Related]
5. Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes.
Petrov AM; Mast N; Li Y; Denker J; Pikuleva IA
Brain Commun; 2020; 2(1):. PubMed ID: 32661514
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Mast N; Saadane A; Valencia-Olvera A; Constans J; Maxfield E; Arakawa H; Li Y; Landreth G; Pikuleva IA
Neuropharmacology; 2017 Sep; 123():465-476. PubMed ID: 28655608
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.
Mast N; Anderson KW; Lin JB; Li Y; Turko IV; Tatsuoka C; Bjorkhem I; Pikuleva IA
J Biol Chem; 2017 Mar; 292(12):4913-4924. PubMed ID: 28190002
[TBL] [Abstract][Full Text] [Related]
9. The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment.
Petrov AM; Mast N; Li Y; Pikuleva IA
FASEB J; 2019 Aug; 33(8):8782-8798. PubMed ID: 31063705
[TBL] [Abstract][Full Text] [Related]
10.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Moutinho M; Nunes MJ; Rodrigues E
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1911-1920. PubMed ID: 27663182
[TBL] [Abstract][Full Text] [Related]
12. The Interplay between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina.
Petrov AM; Astafev AA; Mast N; Saadane A; El-Darzi N; Pikuleva IA
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31842366
[TBL] [Abstract][Full Text] [Related]
13. CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
Petrov AM; Lam M; Mast N; Moon J; Li Y; Maxfield E; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):710-724. PubMed ID: 31062296
[TBL] [Abstract][Full Text] [Related]
14. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma.
Han M; Wang S; Yang N; Wang X; Zhao W; Saed HS; Daubon T; Huang B; Chen A; Li G; Miletic H; Thorsen F; Bjerkvig R; Li X; Wang J
EMBO Mol Med; 2020 Jan; 12(1):e10924. PubMed ID: 31777202
[TBL] [Abstract][Full Text] [Related]
16. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
[TBL] [Abstract][Full Text] [Related]
17. Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes.
Ohyama Y; Meaney S; Heverin M; Ekström L; Brafman A; Shafir M; Andersson U; Olin M; Eggertsen G; Diczfalusy U; Feinstein E; Björkhem I
J Biol Chem; 2006 Feb; 281(7):3810-20. PubMed ID: 16321981
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
19. Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination.
Milagre I; Nunes MJ; Moutinho M; Rivera I; Fuso A; Scarpa S; Gama MJ; Rodrigues E
J Alzheimers Dis; 2010; 22(4):1209-21. PubMed ID: 20930312
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells.
Moutinho M; Nunes MJ; Gomes AQ; Gama MJ; Cedazo-Minguez A; Rodrigues CM; Björkhem I; Rodrigues E
Mol Neurobiol; 2015; 51(3):1489-503. PubMed ID: 25084760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
